Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
:2315
Want to see HK:2315 full AI Analyst Report?
Top Page
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
(2315)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$65.00
â–²(126.48% Upside)
Action:DowngradedDate:04/25/26
The score is driven primarily by improving financial performance (profitability and cash flow turning positive) and supportive technicals (price above key moving averages with positive MACD). These positives are tempered by a demanding valuation (high P/E) and the lack of dividend yield data.
Positive Factors
Revenue scaling & high gross margins
Sustained multi-year revenue growth combined with very high gross margins indicates strong product/service economics and expanding market adoption. Durable unit economics support reinvestment in R&D and partnerships, enabling scalable margin-accretive growth over multiple years.
Negative Factors
Durability risk from recent losses and FCF dip
Although profitability has emerged, the company was loss-making through 2023 and saw free cash flow decline in 2025, highlighting sensitivity to execution. In biotech, swings in program timing or partner activity can quickly reverse margins and cash, testing durability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue scaling & high gross margins
Sustained multi-year revenue growth combined with very high gross margins indicates strong product/service economics and expanding market adoption. Durable unit economics support reinvestment in R&D and partnerships, enabling scalable margin-accretive growth over multiple years.
Read all positive factors
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$24.51B
Dividend YieldN/A
Average Volume (3M)488.12K
Price to Earnings (P/E)73.2
Beta (1Y)1.12
Revenue Growth40.78%
EPS Growth410.73%
CountryHK
Employees1,117
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.26
Shares Outstanding110,781,920
10 Day Avg. Volume755,126
30 Day Avg. Volume488,121
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)5.83
Price to Sales (P/S)9.20
P/FCF Ratio44.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$57.72Price Target Upside101.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.74
Revenue Forecast (FY)HK$1.86B
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs worldwide. The company's pipeline includes 12 core products, among which two products are in Phase II multi-re...
How the Company Makes Money
null...
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
70
Positive
Cash Flow
66
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.38B | 980.45M | 716.91M | 533.88M | 354.56M |
| Gross Profit | 1.05B | 761.52M | 506.03M | 391.75M | 247.44M |
| EBITDA | 419.49M | 303.80M | -97.87M | -465.86M | -378.12M |
| Net Income | 173.20M | 33.54M | -382.95M | -602.16M | -545.58M |
Balance Sheet | |||||
| Total Assets | 3.72B | 2.42B | 2.45B | 2.80B | 2.30B |
| Cash, Cash Equivalents and Short-Term Investments | 1.56B | 381.18M | 408.09M | 611.27M | 566.45M |
| Total Debt | 584.09M | 570.28M | 544.11M | 415.28M | 89.80M |
| Total Liabilities | 1.54B | 1.58B | 1.66B | 1.65B | 1.05B |
| Stockholders Equity | 2.17B | 834.06M | 785.89M | 1.15B | 1.25B |
Cash Flow | |||||
| Free Cash Flow | 282.43M | 174.12M | -203.26M | -543.94M | -564.45M |
| Operating Cash Flow | 370.25M | 211.25M | -76.65M | -303.27M | -365.78M |
| Investing Cash Flow | -184.86M | -137.12M | -100.28M | -153.74M | -84.13M |
| Financing Cash Flow | 979.86M | -92.03M | -37.82M | 587.20M | 219.44M |
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Technical Analysis
Positive
28.70
Price Trends
53.50
Positive
44.10
Positive
34.45
Positive
Market Momentum
2.13
Positive
53.03
Neutral
28.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2315, the sentiment is Positive. The current price of 28.7 is below the 20-day moving average (MA) of 57.35, below the 50-day MA of 53.50, and below the 200-day MA of 34.45, indicating a bullish trend. The MACD of 2.13 indicates Positive momentum. The RSI at 53.03 is Neutral, neither overbought nor oversold. The STOCH value of 28.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2315.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$24.51B | 73.24 | 8.62% | ― | 40.78% | 410.73% | |
58 Neutral | HK$14.28B | -86.94 | -11.81% | ― | 219.26% | 87.63% | |
54 Neutral | HK$20.32B | -9.33 | -12.74% | ― | 57.92% | -23.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$10.16B | 30.77 | 24.17% | ― | 154.21% | ― | |
41 Neutral | HK$21.34B | -25.84 | -17.26% | ― | 66.66% | 7.19% |
* Healthcare Sector Average
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
51.70
39.64
328.69%
HK:1672
Ascletis Pharma, Inc.
16.68
10.00
149.70%
HK:2157
Lepu Biopharma Co. Ltd. Class H
5.40
0.80
17.39%
HK:2162
Keymed Biosciences, Inc.
75.25
30.25
67.22%
HK:2171
CARsgen Therapeutics Holdings Ltd.
22.76
6.78
42.43%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
6.87
-3.91
-36.27%
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Corporate Events
Biocytogen Sets 2025 AGM to Decide Profit Plan, Capital Changes and Credit Facilities
Apr 23, 2026
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has convened its 2025 annual general meeting for May 21, 2026, to be held both physically in Beijing and virtually online. Shareholders will review the board’s 2025 work report and vote on reappo...
Biocytogen Sets April Board Meeting to Approve First-Quarter 2026 Results
Apr 15, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a Hong Kong-listed biopharmaceutical company, announced that its board includes a mix of executive, non-executive, independent non-executive, and employee directors. This governance structure is desi...
Biocytogen, Sihuan Form Strategic Alliance on Antibody Drugs and Weight-Loss Therapies
Apr 1, 2026
Biocytogen Pharmaceuticals has entered a strategic partnership with Sihuan Pharmaceutical Holdings Group to combine Biocytogen’s fully human antibody discovery and AI-driven platforms with Sihuan’s strengths in drug development, manufa...
Biocytogen Publishes Audited 2025 Results and Sets Timeline for Full Annual Report
Mar 26, 2026
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has released its audited annual results for the year ended 31 December 2025, which have been reviewed by the board’s audit committee. The company stated that the annual results announcement inclu...
Biocytogen Partner NEOK Bio Wins FDA IND Clearance for Bispecific-Based ADC NEOK002
Mar 26, 2026
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. is a China-based biopharma developer specializing in fully human bispecific antibodies and related antibody-drug conjugates, underpinned by its RenLite platform that supports partnerships with external...
Biocytogen Updates Articles to Reflect STAR Market A-Share Listing and Expanded Capital
Mar 26, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. plans to amend its articles of association to formally reflect changes in its share capital following the issuance of 47,500,000 A shares and its listing on the STAR Market of the Shanghai Stock Excha...
Biocytogen Schedules Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 16, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has scheduled a board meeting for 26 March 2026 to review and approve the audited annual results for the financial year ended 31 December 2025. The board will also deliberate on the potential declarat...
Biocytogen forecasts sharp 2025 profit surge on overseas growth and industry rebound
Feb 26, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. reported strong preliminary results for 2025, with total operating revenue rising 40.63% year on year to RMB1.38 billion and net profit attributable to shareholders surging more than fourfold to RMB17...
Biocytogen Shareholders Approve New Non-Executive Director at 2026 EGM
Feb 12, 2026
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. reported the poll results of its first extraordinary general meeting of 2026, held in a hybrid physical and virtual format in Beijing on February 12, with shareholders representing 59.1% of voting shar...
Biocytogen Sets Out Board Structure and Committee Roles
Feb 12, 2026
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has disclosed the composition of its board of directors, led by Chairman and CEO Dr. Shen Yuelei, and including executive, non-executive, independent non-executive and an employee director. The announc...
Biocytogen Forecasts Profit Surge on Overseas Expansion and Industry Recovery in 2025
Jan 29, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has issued an inside information announcement of its unaudited estimated financial results for 2025, projecting revenue of RMB1.37 billion to RMB1.39 billion, a year-on-year increase of about 40%, and...
Biocytogen Proposes Appointment of SDIC Investment Manager as Non-Executive Director
Jan 27, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has proposed the appointment of 35-year-old Liu Hongkang, currently an investment manager at SDIC Venture Capital Management, as a non-executive director, subject to approval by shareholders at an upc...
Biocytogen Calls 2026 Extraordinary Meeting to Vote on New Non-Executive Director
Jan 27, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has called its first extraordinary general meeting of 2026 for 12 February in a hybrid format, combining a physical meeting in Beijing with an online e-meeting system to allow broader shareholder part...
Biocytogen Sets February 2026 Date and Share Register Closure for Extraordinary General Meeting
Jan 26, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has announced that it will convene an extraordinary general meeting (EGM) on 12 February 2026 at 2:00 p.m., to be held in a hybrid format combining a physical meeting in Beijing and an online virtual ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.